At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8 enrolled
Drug / intervention
Integra® Gentrix® Surgical Matrixdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Analysis of the Use of Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair as Long Term Follow Up to T-GENVIH-002 Study
In Brief
An observational study evaluating Integra® Gentrix® Surgical Matrix for Hernia and 3 related conditions. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The T-GENVIH-003 study will collect additional, longer term performance data of Gentrix® Surgical Matrix used for reinforcement of ventral hernia repairs from a subset population (i.e., the twenty-one minimally invasive surgical approach cases) from the prior T-GENVIH-002 study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartSep 2023
First PostedSep 2023
Primary CompletionJan 2024
TodayJul 2026
First PostedSep 13, 2023
Enrollment StartSep 12, 2023
Primary CompletionJan 19, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.8 years ago
Interventions
Integra® Gentrix® Surgical Matrixdevice
Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.